Drug Trial Radar · NCT07219043
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
81
Planned (sponsor's estimate)
Start
Jan 5, 2026
Primary completion
Feb 10, 2028
Study completion Feb 10, 2028
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Oct 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and later developed a condition called microvascular inflammation (MVI). MVI is a type of injury to small blood vessels in the transplanted kidney and may be a sign of rejection by the body. It can lead to serious kidney problems over time. In many cases, MVI is caused by antibodies that attack the transplanted kidney. But in some people, MVI happens without these antibodies. This type of MVI is called isolated MVI. There are currently no approved treatments for isolated MVI. The main goal of the study is to learn about the effect felzartamab has on inflammation in the transplanted kidney. The main question researchers want to answer is: • How many participants have no signs of active inflammation in the transplanted kidney after 24 weeks of treatment with felzartamab? Researchers will also study how felzartamab affects kidney function, immune activity, and overall health. They will monitor safety through kidney biopsies, lab tests, and by recording adverse events throughout the study. Adverse events are health problems that may or may not be caused by the study drug. The study will be done in 2 parts as follows: * Participants will be randomly assigned to receive either felzartamab or a placebo. A placebo looks like the study drug but contains no real medicine. * In Part A, participants will receive their assigned drug for 24 weeks. Neither the researchers nor the participants will know who is receiving felzartamab or placebo. * Part B will last another 28 weeks. All participants will receive felzartamab and both participants and researchers will know this. * All treatments will be given by intravenous (IV) infusion at the study site. * Participants will have kidney biopsies at the start of the study, at Week 24, and at Week 52 to help measure changes in inflammation. * Participants will stay in the study for about 1 year.
Conditions
- Microvascular Inflammation
Interventions
FelzartamabDrug
Administered IV
PlaceboDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants Who Achieve Biopsy-proven Histologic Resolution (BPHR)Time frame: Week 24
Locations
53 sites in 11 countries. Site status is shown where the registry gives one.
Loma Linda University Medical Center
Loma Linda, California · Recruiting
Keck Hispital of University of Southern California (USC)
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
University of California, Los Angeles
Los Angeles, California · Recruiting
Providence St. Joseph Hospital Orange
Orange, California · Recruiting
Sutter Health - California Pacific Medical Center
San Francisco, California · Recruiting
University of California San Fransisco (UCSF) Medical Center
San Francisco, California · Recruiting
University of Colorado
Aurora, Colorado · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
The University of Kansas Medical Center
Kansas City, Kansas · Recruiting
University of Michigan Medical Center
Ann Arbor, Michigan · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Cooperman Barnabas Medical Center
West Orange, New Jersey · Recruiting
Duke University Hospital
Durham, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
The Ohio State University
Columbus, Ohio · Recruiting
Penn Medicine - Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
Houston Methodist Hospital
Houston, Texas · Recruiting
Virginia Commonwealth University (VCU) Medical Center (Main Hospital) Hume-Lee Transplant Center
Richmond, Virginia · Recruiting
University of Washington Medical Center
Seattle, Washington · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Clínica Privada Vélez Sarsfield
Córdoba, Argentina · Recruiting
Instituto de Trasplante y Alta Complejidad (ITAC)
Buenos Aires, Ciudad Autónoma de Buenos Aires (caba), Argentina · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Princess Alexandra Hospital
Brisbane, Queensland, Australia · Recruiting
Royal Melbourne Hospital
Parkville, Victoria, Australia · Recruiting
Fiona Stanley Hospital
Murdoch, Western Australia, Australia · Recruiting
Medizinische Universität Wien
Vienna, Austria · Recruiting
Hospital do Rim - Fundação Oswaldo Ramos
São Paulo, Brazil · Recruiting
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)
São Paulo, Brazil · Recruiting
Hospital de Base da Faculdade de Medicina de São José do Rio Preto
Vila São José, São José Do Rio Preto, Brazil · Recruiting
Alberta Health Services (AHS) - University of Alberta Hospital
Edmonton, Alberta, Canada · Recruiting
Vancouver General Hospital
Vancouver, British Columbia, Canada · Recruiting
Providence Health Care - St. Paul's Hospital
Vancouver, British Columbia, Canada · Recruiting
Institut klinicke a experimentalni mediciny (IKEM)
Prague, Czechia · Recruiting
Centre Hospitalier Universitaire (CHU) de Bordeaux - Hôpital Pellegrin
Bordeaux, France · Recruiting
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.